Search Results
Results found for "assay development"
- Emerging approaches for decoding neuropeptide transmission
These complex properties have driven the need for development of specialized tools that can sense neuropeptide
- G protein-coupled receptor signaling: transducers and effectors
As new technologies are developed and applied to studying GPCR structure and their downstream effectors
- 📰 GPCR Weekly News - January 2 to 8, 2023
Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Verily links up with Sosei Heptares for GPCR drug discovery
Sosei Heptares, which have struck a research agreement to discover new GPCR targets that’ll fuel the development
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
approved drugs over previous decades—but the two-year-old biotech believes the area is still ripe for development
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and
- 📰 GPCR Weekly News
GPCR Binders, Drugs, and more Persistent challenges in the development of an mGlu7 PAM in vivo tool compound Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
recognizes the combination of Steyaert’s fundamental research and his ability to apply the research to the development
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Collaboration, Chemistry, and the Pivot That Changed the Project Goal: Develop a photo-switchable GPCR
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development
- 📰 GPCR Weekly News
Drugs, and more Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability BioSpace Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Arginine 125 Is an Essential Residue for the Function of MRAP2
protein-coupled receptors helps in elucidating the metabolic pathways involved in metabolic dysfunction and in developing
- 📰 GPCR Weekly News, September 25 to October 1, 2023
collaborates with Exscientia plc in deal worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its
- 📰 GPCR Weekly News, April 15 to 21, 2024
Hoare's workshop for individuals who live and work in developing countries. We define a developing country based on World Bank Classifications for its 2024 fiscal year.
- AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors
Recently, AlphaFold2 has been developed to predict structure models of many functionally important proteins
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
findings provide new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
However, the drug development of CX3CR1 is hampered partially by the lack of structural information.
- 📰 GPCR Weekly News, July 24 to July 30, 2023
GPCR Binders, Drugs, and more Development of a V5-tag-directed nanobody and its implementation as an Discovery Industry Indivior Announces Q2/H1 2023 Financial Results Scientists Discover a New Way To Develop
- GPCR Therapeutics Expands Scientific Advisory Board
Jon Wigginton will provide scientific expertise to support the company’s research and clinical development
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Hear the sounds: the role of G protein-coupled receptors in the cochlea
The research of GPCRs in the cochlea is essential for the understanding of the cochlea development, hearing
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
pathological expression profile of GPR84 and, in the absence of direct structural information, recent developments
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
Biological Keys to Medical Therapies From Structure to Solution: How Structural Biology Informs the Development Biologist GPCR Activation and Signaling Exploring Bias in GPCR Signaling and its Implication in Drug Development
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
(Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization
- The microglial endocannabinoid system similarly regulated by lipopolysaccharide and interferon gamma
capacity of microglia to synthesize, degrade, and respond to cannabinoids which has implications for the development
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
As a result, there is an ongoing need to develop novel approaches to monitor and to modulate GPCR activation
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic




